Who is eligible for clinical trial NCT06291376?

Participants must meet the protocol's inclusion criteria for Immunoglobulin A Nephropathy. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06291376 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-17

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (NCT06291376)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Alexion Pharmaceuticals, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (11 items).

Location: Research Site — Alabaster, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Documentation of IgAN diagnosis established on kidney biopsy obtained any time prior to or during the Screening Period for participants with eGFR ≥ 30 mL/min/1.73 m\^2.
For participants in the AdKD cohorts, eGFR 20 to 29 mL/min/1.73 m2 a kidney biopsy is required within 6 months prior to Screening or during the Screening Period.
UPCR ≥ 0.75 g/g or UP ≥1 g/day calculated from the mean of two 24-hour urine during the Screening Period.
Estimated GFR ≥ 30 mL/min/1.73 m2 at Screening.
Stable and maximum allowed or tolerated RAASI (ACEI and/or ARB) dose for ≥ 3 months prior to Screening with no planned change during Screening through Week 106.
Participants who are receiving SGLT2I, DEARA, MRA or ERA must be on a stable and maximum allowed or tolerated dose for ≥ 3 months prior to Screening with no planned change in dose through Week 106.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Diagnosis of rapid progressive glomerulonephritis as measured by eGFR loss ≥ 50% over a period of 3 months prior to Screening.
Secondary IgAN (eg, due to systemic lupus erythematosus (SLE), cirrhosis, or celiac disease; IgAV-N may be eligible).
Concomitant clinically significant renal disease other than IgAN.
Prior use of immunosuppressive treatment within 3 months of screening.
Uncontrolled diabetes mellitus with glycosylated hemoglobin (HbA1c) \> 8.5%.
Henoch-Schonlein purpura (IgAV) requiring systemic immunosuppressive therapy within 12 months of Screening.
History of kidney transplant or planned kidney transplant during the Treatment Period.
Splenectomy or functional asplenia.
History of Neisseria meningitidis infection.
Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (246 Sites)

Showing the first 25 of 246 sites.

Research Site — Alabaster, Alabama
Research Site — Phoenix, Arizona
Research Site — Los Angeles, California
Research Site — Los Angeles, California
Research Site — Los Angeles, California
Research Site — Orange, California
Research Site — San Bernardino, California
Research Site — San Diego, California
Research Site — San Francisco, California
Research Site — Stanford, California
Research Site — Torrance, California
Research Site — Valencia, California
Research Site — Bay Pines, Florida
Research Site — Miami, Florida
Research Site — Orlando, Florida
Research Site — Acworth, Georgia
Research Site — Atlanta, Georgia
Research Site — Lawrenceville, Georgia
Research Site — New Orleans, Louisiana
Research Site — Boston, Massachusetts
Research Site — Boston, Massachusetts
Research Site — Boston, Massachusetts
Research Site — Worcester, Massachusetts
Research Site — Minneapolis, Minnesota
Research Site — Minneapolis, Minnesota

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Immunoglobulin A Nephropathy

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US — Boston, Massachusetts
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) — Birmingham, Alabama
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Huntsville, Alabama
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy — Birmingham, Alabama

Explore by condition: All Immunoglobulin A Nephropathy clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗